Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Immunosuppressant to enter clinical trials
December 12th, 2004
LifeCycle Pharma announced that it has initiated clinical trials on an improved tablet formulation of the immunosuppressant, tacrolimus. "This is the second product that we have advanced into clinical trials this year," said Jan Møller Mikkelsen, president and CEO of LifeCycle Pharma. "Next year, we will further progress our product pipeline by initiating clinical trials on two new products as well as on line extensions and fixed-dose combinations of our existing products." "In our improved tacrolimus clinical study, we will test multiple tablet formulations with different release profiles," added Michael Beckert, vice president of clinical and...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
